The xanthine oxidase inhibitor allopurinol effectively lowers the plasma level of uric acid and the drug has become widely used in the treatment of gout, especially in patients with renal failure, uric acid calculi, or intolerance to uricosuric agents (Scott, Hall, and Grahame, 1966) . Various theoretical complications of treatment have been considered from time to time, such as possible incorporation of ribonucleotide into genetic material or the effects of crystals of allopurinol in voluntary muscle, as discussed below. For these reasons it was thought reasonable a few years ago to determine the effect of discontinuing allopurinol therapy in gouty patients who were not over-producers of uric acid and whose renal function was not impaired.
The xanthine oxidase inhibitor allopurinol effectively lowers the plasma level of uric acid and the drug has become widely used in the treatment of gout, especially in patients with renal failure, uric acid calculi, or intolerance to uricosuric agents (Scott, Hall, and Grahame, 1966) . Various theoretical complications of treatment have been considered from time to time, such as possible incorporation of ribonucleotide into genetic material or the effects of crystals of allopurinol in voluntary muscle, as discussed below. For these reasons it was thought reasonable a few years ago to determine the effect of discontinuing allopurinol therapy in gouty patients who were not over-producers of uric acid and whose renal function was not impaired.
Plan of study Medication was discontinued in 33 patients with gout (32 men and one woman), with a mean age of 58 years (range 33-75 yrs). In five of them the drug would have had to be discontinued in any case because of a skin rash or malaise probably attributable to the drug; in 28 the drug was stopped in the absence of side effects after full discussion with individual patients. None of these latter patients had impairment of renal function (as estimated by blood urea) and none were over-producers of uric acid as indicated by a 24-hour urinary uric acid excretion of less than 600 mg on a low-purine diet.
The mean length of history of gout before starting treatment had been 15 years (range 05-42 yrs), with an average of 4-5 attacks per year before starting therapy. The mean duration of allopurinol treatment before the drug was discontinued was 93 weeks (range 19-236 wks), and the mean duration off allopurinol at the time this analysis was made was 86 weeks (range 14-210 wks).
Results
(1) PLASMA URIC ACID The mean level of plasma uric acid before starting therapy had been 8-4 mg/100 ml (SD 1 1), falling to 5.5 mg/100 ml (SD 1-2) after allopurinol therapy was established. After the withdrawal of allopurinol, uric acid levels rose to pretreatment figures in all patients (mean 8-8 within one week of discontinuation, regardless of the duration of therapy (Fig. 1) . In a few instances, however, pretreatment values were not regained until 2 or 3 weeks after stopping the drug.
(2) BLOOD UREA Pretreatment blood urea levels had been 45 mg/ 100 ml or below in all the patients in whom allopurinol was stopped in the absence of side effects, but was higher in some of the patients in whom the drug was stopped because of such side effects. The mean blood urea in all patients before allopurinol was started had been 41 mg/100 ml (SD 10), and showed no significant change during allopurinol treatment (39 mg/100 ml; SD 12), or after allopurinol was discontinued (37 mg/100 ml; SD 11).
Figures for creatinine clearance both before and after treatment were available in only five subjects; these showed no change after discontinuation (mean 105 ml/min before treatment, 114 ml/min after treatment was discontinued). Up to the time this analysis was made there had been a recurrence of gouty arthritis in twelve patients; 21 patients have remained well and free of symptoms. Thirteen patients have restarted the drug (after a mean duration off treatment of 55 weeks). The usual reason for restarting treatment has been the recurrence of gouty arthritis, but in four patients the drug was started relatively early after it was discontinued, because either the patient or his physician preferred to do so; treatment was restarted in one patient because of uric acid crystalluria (though his 24-hour urinary uric acid before treatment had not been raised and previous microscopy of urine had shown no abnormality). Treatment was restarted in one patient who had remained symptom-free for 3 years off the drug but who was to have a prostatectomy operation; it was thought wise to avoid a risk of postoperative gout.
At the time of analysis twenty patients were still not taking allopurinol after a mean duration off treatment of 107 weeks. Fifteen of these patients had remained free of gout and five had had a mild recurrence. The course of all 33 patients is indicated in Fig. 2 . Table. There is no significant difference between the two groups with regard to the mean age at stopping allopurinol, mean duration of clinical gout, mean duration of allopurinol treatment, mean daily dose of allopurinol, and the mean initial plasma uric acid. Those patients having no recurrence of gout, however, are seen to have had a better control of plasma urate level while taking the drug (mean 5-1 mg/100 ml) than those who have had a recurrence of gouty arthritis (mean 6-2 mg/100 ml).
Discussion
Apart from the occasional occurrence of skin rashes, particularly in patients with renal failure, allopurinol appears to have remarkably few side effects. Because of its inhibitory effect on purine biosynthesis (in addition to its action as an inhibitor of xanthine oxidase), the anticipated complication of xanthine stone formation occurs with extreme rarity. It has in fact been recorded only in patients with the Lesch-Nyhan syndrome, where allopurinol fails to suppress purine biosynthesis and the urinary excretion rate of the oxypurines hypoxanthine and xanthine is high (Seegmiller, 1968 ; Greene, Fujimoto, and Seegmiller, 1969) , and in a patient with lymphosarcoma who received allopurinol for control of hyperuricaemia (Band, Silverberg, Henderson, Ulan, Wensel, Banerjee, and Little, 1970) . Possible effects of allopurinol on iron metabolism have not been confirmed (Emmerson, 1966; Boyett, Vogler, de Paula Furtado, and Schmidt, 1968) , but it appears that the drug increases the risk of bone marrow damage in (Nelson, Bugge, Krasny, and Elion, 1973; Nelson and Elion, 1974 ). The present study was begun at a time when the last two possibilities were perhaps causing more anxiety than is the case at present; it was consideredjustifiable to discontinue allopurinol in a group ofgouty patients without over-production of uric acid and without renal failure, and to observe their progress. Plasma levels of uric acid rose rapidly to pretreatment values in all subjects, but gouty arthritis has recurred in only a minority of them and attacks seem to have been mild. Presumably the total body content of urate is depleted during the period of treatment, and time is required for re-accumulation ofurate, its precipitation in solid form, and the subsequent development of gouty arthritis. In this context it is of interest that there was no significant difference with regard to duration of allopurinol treatment between those subjects who have not yet had a recurrence of gouty arthritis compared with those who have; but control of plasma urate levels while taking the drug had been better in the former than in the latter.
Assessment of renal function was not entirely satisfactory because some of the patients were seen for the first time after treatment was started, and in most subjects levels of creatinine clearance before, during, and after treatment were not available for comparison. The few which were, however, showed no change and levels of blood urea in all subjects remained constant, with no indication of any overall change either during treatment or after its cessation.
Evidently allopurinol can be discontinued in patients with uncomplicated gouty arthritis for relatively long periods without recurrence of their symptoms. It is currently accepted practice, however, that once a decision has been taken to start allopurinol (or uricosuric) treatment this should be continued indefinitely, and the results of the present study do not give any grounds for changing this concept.
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